At Bay Area Lyme Foundation, we are excited about the potential for significant breakthroughs in medical research being led by the following scientists.
Dr. Aucott is a renowned expert in clinical research on the diagnosis and epidemiology of Lyme disease. He is the founder and president of Lyme Disease Research Foundation, a public nonprofit organization founded to promote research and education in Lyme disease.
Dr. Barbour is a pioneer in the Lyme disease field who worked with Willy Burgdorfer to identify the cause of Lyme and was the first to isolate and grow the Borrelia burgdorferi bacteria in a laboratory. He is currently focused on understanding genes that are involved in the persistence of infection or inflammation.
Dr Chase Beisel was awarded the 2016 Emerging Leader Award to explore the potential ability of CRISPR-Cas genome targeting to kill the bacteria that causes Lyme.
Dr. Blum is a 2014 Bay Area Lyme Foundation Emerging Leader Award winner and fellow at Stanford University in the laboratory of Dr. William Robinson, where she is currently working on DNA sequencing of human antibody responses to Borrelia burgdorferi infection.
Dr. Bouquet is a 2014 Bay Area Lyme Foundation Emerging Leader Award winner and fellow at UCSF in the laboratory of Dr. Charles Chiu studying infectious disease, particularly Lyme and other tick-borne illnesses.
Dr. Branda's research focuses on improving patient care through the development of new diagnostic strategies and the optimization of laboratory tests and antimicrobial agents, including tick-borne illnesses such as Lyme borreliosis, anaplasmosis, and tularemia.
Dr. Capon is a serial inventor whose patents have been licensed for a number of blockbuster biotech products representing over $12 billion in annual sales. He is applying his creative thinking to the problem of Lyme.
Dr. Chiu is an expert in the development and implementation of advanced genomic technologies for pathogen discovery and clinical diagnostics including microarrays and next generation sequencing.
Dr. Embers' work focuses on antibiotic efficacy against Lyme disease; and immunodiagnosis for the Lyme-causing B. burgdorferi infection.
Dr. Eshoo serves as the Director of New Technology Development at Ibis Biosciences where he leads several projects relating to development and assessment of new diagnostic technologies.
Dr. Garbett applies biophysical approaches to the study of biomolecules and their interactions, with particular emphasis on the development of new technologies for medical diagnostics and drug development.
Dr. Garland has been leading the research efforts at Agile Sciences focused on a new treatment attacking the biofilms that surround the borrelia burgdorferi bacteria protecting it from human immunological response.
Dr. Britton Grasperge is a 2016 Emerging Leader Award recipient and a veterinary clinical pathologist with a research interest in tick-borne diseases.
Dr. Emir Hodzic received Veterinary, Masters and Ph.D. degrees from University of Sarajevo, School of Veterinary Medicine, Bosnia and Herzegovina. He did postdoctoral training at the Section of Comparative Medicine, Yale University School of Medicine where he focused on animal models for Lyme disease and human granulocytic ehrlichiosis. Currently, Dr. Hodzic is a Director at the Real-Time PCR Research & Diagnostics Core Facility at the School of Veterinary Medicine, University of California, Davis where he is researching post-antibiotic persistence of Borrelia burgdorferi.
Dr. Richard Horowitz is a board certified internist in private practice in Hyde Park, N.Y. He is medical director of the Hudson Valley Healing Arts Center, an integrative medical center which combines both classical and complementary approaches in the treatment of Lyme Disease and other tick-borne disorders. He has been treating Lyme patients for the last 29 years, and he is now undertaking a data mining project with support of Bay Area Lyme Foundation.
Dr. Horn facilitates the development of biorepositories and other bio-based technologies for medical research and is the Principal Investigator for the new National Lyme Biorepository.
Dr. Hood's outstanding contributions have had a resounding effect on the advancement of science since the 1960s. He has made many seminal discoveries in the fields of immunology, neurobiology and biotechnology and, most recently, systems biology and its applications to cancer and neurodegenerative disease.
Dr. Johnson is currently developing a new Lyme diagnostic using single-layered molecular graphene sheets attached to antibodies to identify specific proteins carried by the Borrelia burgorferi bacteria.
Dr. Lise E. Nigrovic is the Director of Education, Clinical Research Center and Senior Associate Physician in Medicine at Boston Children’s Hospital and an Associate Professor of Pediatrics and Emergency Medicine at Harvard Medical School. Her current work is focused on a pediatric multi‐center Lyme disease research network with biosample collection.
Dr. Nieto's research focus is on infectious diseases, vector biology, and the ecological evolution and transmission of disease from wildlife to humans and domestic animals.
Dr. Long is applying his expertise in model systems to understand genes that influence the body’s response to the Lyme bacteria, Borrelia burgdorferi.
Dr. Miller has studied the Lyme disease spirochete Borrelia burgdorferi for her entire 15-year career. Her work focuses on the pathogenesis of B. burgdorferi and its interactions with the host immune system. She is currently employed by Agile Sciences.
Dr. Pollock's research has a special interest on the development and evaluation of novel diagnostic tests for infectious diseases and related applications. Her Lyme-related work has included the discovery of novel biomarkers of early Lyme borreliosis.
Dr. Price has won numerous awards including an American Cancer Society Postdoctoral Fellowship, a NIH Howard Temin Pathway to Independence Award, a NSF CAREER award, and a young investigator award from the Roy J. Carver Charitable Trust.
Dr. Rajadas is Director of the Biomaterials and Advanced Drug Delivery Lab (BioADD) and Assistant Director of Cardiovascular Pharmacology at Stanford School of Medicine. His recent research, funded by Bay Area Lyme Foundation, identified 20 FDA-approved compounds that were more effective in inhibiting persistent Lyme bacteria than standard antibiotic treatment.
Dr. Robinson works to develop novel therapies for practical patient care, including the application of antibody sequencing technologies for the treatment of Lyme and other autoimmune diseases.
Dr. Salkeld studies the community ecology of wildlife disease, particularly host-parasite systems, and the implications for conservation and public health.
Dr. Soloski is a co-Principal Investigator on the landmark SLICE clinical trial and specializes in the study of certain immune cells (T-cells) and their role in immune recognition, autoimmunity, and host response to infection in acute and chronic disease states.